SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 24, 2006--FibroGen, Inc., today announced the appointment of Tim C. Opler as Vice President of Strategy. Mr. Opler brings to FibroGen 15 years of experience in financial services and academia. At FibroGen, Mr. Opler will focus on matters involving strategic planning, organizational development, and financial markets.
Mr. Opler was most recently Managing Director at Credit Suisse in healthcare investment banking where he was responsible for a series of financial and strategic transactions in the biotechnology and pharmaceutical areas. Mr. Opler began his Wall Street career in 1997 as a Director at Deutsche Bank. Earlier, he was a finance professor at Southern Methodist University and The Ohio State University. He began his career as a research analyst at the Rand Corporation and held several teaching positions at University of California, Los Angeles.
“Tim will play a key role in strategic planning and organizational development in preparation for the growth and maturation of our product portfolio,” said Thomas B. Neff, Chief Executive Officer of FibroGen. “I look forward to Tim’s contributions and initiatives to help us develop a strong, vertically-integrated biopharmaceutical organization.”
Mr. Opler received a Ph.D. in Economics from UCLA and a B.S. from Florida State University.
About FibroGen
FibroGen, Inc., is a biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, ischemic disease, cancer, and other areas of unmet medical need. FibroGen also develops and produces recombinant human collagens and gelatins using unique production technology that provides the basis for FibroGen’s proprietary cosmetic dermal filler and biomaterials supply business.
For more information about FibroGen, Inc., please visit www.fibrogen.com.
Contact: FibroGen Laura Hansen, 650-866-7828 lhansen@fibrogen.com
Source: FibroGen, Inc.
